The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go

Elizabeth D. Thompson; Nicholas J. Roberts; Laura D. Wood; James R. Eshleman; Michael G. Goggins; Scott E. Kern; Alison P. Klein; Ralph H. Hruban

doi:10.1038/s41379-020-0629-6

The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go

Elizabeth D. Thompson, Nicholas J. Roberts, Laura D. Wood, James R. Eshleman, Michael G. Goggins, Scott E. Kern, Alison P. Klein, Ralph H. Hruban

School of Medicine

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

The publication of the “Pan-Cancer Atlas” by the Pan-Cancer Analysis of Whole Genomes Consortium, a partnership formed by The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC), provides a wonderful opportunity to reflect on where we stand in our understanding of the genetics of pancreatic cancer, as well as on the opportunities to translate this understanding to patient care. From germline variants that predispose to the development of pancreatic cancer, to somatic mutations that are therapeutically targetable, genetics is now providing hope, where there once was no hope, for those diagnosed with pancreatic cancer.

Original language	English (US)
Pages (from-to)	2544-2563
Number of pages	20
Journal	Modern Pathology
Volume	33
Issue number	12
DOIs	https://doi.org/10.1038/s41379-020-0629-6
State	Published - Dec 2020

ASJC Scopus subject areas

General Medicine

Access to Document

10.1038/s41379-020-0629-6

Cite this

@article{6da51b3a6da04548bca53945a90891a1,

title = "The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go",

abstract = "The publication of the “Pan-Cancer Atlas” by the Pan-Cancer Analysis of Whole Genomes Consortium, a partnership formed by The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC), provides a wonderful opportunity to reflect on where we stand in our understanding of the genetics of pancreatic cancer, as well as on the opportunities to translate this understanding to patient care. From germline variants that predispose to the development of pancreatic cancer, to somatic mutations that are therapeutically targetable, genetics is now providing hope, where there once was no hope, for those diagnosed with pancreatic cancer.",

author = "Thompson, {Elizabeth D.} and Roberts, {Nicholas J.} and Wood, {Laura D.} and Eshleman, {James R.} and Goggins, {Michael G.} and Kern, {Scott E.} and Klein, {Alison P.} and Hruban, {Ralph H.}",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.",

year = "2020",

month = dec,

doi = "10.1038/s41379-020-0629-6",

language = "English (US)",

volume = "33",

pages = "2544--2563",

journal = "Modern Pathology",

issn = "0893-3952",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - The genetics of ductal adenocarcinoma of the pancreas in the year 2020

T2 - dramatic progress, but far to go

AU - Thompson, Elizabeth D.

AU - Roberts, Nicholas J.

AU - Wood, Laura D.

AU - Eshleman, James R.

AU - Goggins, Michael G.

AU - Kern, Scott E.

AU - Klein, Alison P.

AU - Hruban, Ralph H.

PY - 2020/12

Y1 - 2020/12

N2 - The publication of the “Pan-Cancer Atlas” by the Pan-Cancer Analysis of Whole Genomes Consortium, a partnership formed by The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC), provides a wonderful opportunity to reflect on where we stand in our understanding of the genetics of pancreatic cancer, as well as on the opportunities to translate this understanding to patient care. From germline variants that predispose to the development of pancreatic cancer, to somatic mutations that are therapeutically targetable, genetics is now providing hope, where there once was no hope, for those diagnosed with pancreatic cancer.

AB - The publication of the “Pan-Cancer Atlas” by the Pan-Cancer Analysis of Whole Genomes Consortium, a partnership formed by The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC), provides a wonderful opportunity to reflect on where we stand in our understanding of the genetics of pancreatic cancer, as well as on the opportunities to translate this understanding to patient care. From germline variants that predispose to the development of pancreatic cancer, to somatic mutations that are therapeutically targetable, genetics is now providing hope, where there once was no hope, for those diagnosed with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85088529281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088529281&partnerID=8YFLogxK

U2 - 10.1038/s41379-020-0629-6

DO - 10.1038/s41379-020-0629-6

M3 - Review article

C2 - 32704031

AN - SCOPUS:85088529281

SN - 0893-3952

VL - 33

SP - 2544

EP - 2563

JO - Modern Pathology

JF - Modern Pathology

IS - 12

ER -

The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this